Previous studies using hypoxia PET have shown significant reduction of tumor hypoxia (reoxygenation) during primary radiochemotherapy (RCT) of HNSCC and a significant correlation between reoxygenation on hypoxia PET and local control. Assessment of tumor hypoxia using MRI would offer independence from hypoxia PET tracer availability. The apparent MRI transverse relaxation time T2* has been proposed as an imaging biomarker and as a potential surrogate for hypoxia PET. The aim of this study was to assess the effect of primary RCT on T2* at an early (week 2) and late (week 5) time point during RCT and to analyse the relation between T2* and established hypoxia PET tracer 18F-misonidazole PET/CT (FMISO PET) and standard 18F-FDG PET/CT (FDG PET). In 10 T2-4N+ HNSCC patients, FDG PET was obtained at baseline and repeat FMISO PET and 3 Tesla MRI T2* in weeks 0, 2 and 5. MRI gross tumor volumes for tumor and lymph nodes (GTV-T, GTV-LN) were contoured and FMISO PET derived hypoxic tumor/lymph node subvolumes (HSV-T, HSV-LN) and complementary non-hypoxic subvolumes (nonHSV-T, nonHSV-LN) were generated using a threshold level of 1.4 times the mean SUV FMISO within muscle. Volumes were contoured for all time points (week 0, 2 and 5) individually and mean values for T2* and SUVmean FDG PET were obtained. Within GTVs (T, LN), r2 (FMISO to T2*) was calculated for [FMISO SUVmax GTV/SUVmean muscle] to [T2* mean GTV] and r2 (FMISO to FDG) was calculated for [FMISO SUVmax GTV/SUVmean muscle] to [FDG SUVmax GTV/SUVmean muscle]. From week 0 to 5 GTV-T and GTV-LN decreased by -56% and -63%, respectively and HSV-T and HSV-LN nearly completely resolved (n = 10). Mean T2* signal showed no significant change for GTV-T or GTV-LN. Within HSV-T mean T2* values were smaller compared to nonHSV-T: 15.0+/-4.6 vs. 18.3+/-2.9 (p = 0.051), whereas FDG SUVmean was significantly higher within hypoxic as compared to non-hypoxic regions: HSV-T 12.1+/-5.5 vs. nonHSV-T 6.1+/-2.6 and HSV-LN 10.2+/-3.9 vs. nonHSV-LN 4.7+/-1.9 (week 0, p≤0.026 and p≤0.011). Correlation between FMISO PET and FDG PET was higher than between FMSIO PET and T2*: r2 for GTV-T (FMISO/FDG)=0.81, r2 for GTV-T (FMISO/T2*)=0.32. Marked reduction of tumor hypoxia between week 0, 2 and 5 found on FMISO PET was not accompanied by a significant T2*change within GTVs over time. At baseline, smaller T2* values and significantly larger FDG SUVmean were found within HSV-T as compared to nonHSV-T. These results suggest a relation between tumor oxygenation status and T2* at baseline, however with the correlation coefficient r2 FMISO/T2* being lower than r2 FMISO/FDG. Overall, T2* quantitation was feasible and the findings on T2* imaging warrant further investigations but do not indicate a simple surrogate role for T2* as hypoxia imaging marker due to lack of correlation to established hypoxia marker FMISO PET. Our findings on reduction of FMISO uptake during RCT were in line with previous reports.